212 related articles for article (PubMed ID: 17548494)
21. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis.
Müller FM; Weig M; Peter J; Walsh TJ
J Antimicrob Chemother; 2000 Aug; 46(2):338-40. PubMed ID: 10933673
[No Abstract] [Full Text] [Related]
22. Molecular epidemiology of Candida albicans strains isolated from the oropharynx of HIV-positive patients at successive clinic visits.
Lasker BA; Elie CM; Lott TJ; Espinel-Ingroff A; Gallagher L; Kuykendall RJ; Kellum ME; Pruitt WR; Warnock DW; Rimland D; McNeil MM; Reiss E
Med Mycol; 2001 Aug; 39(4):341-52. PubMed ID: 11556764
[TBL] [Abstract][Full Text] [Related]
23. Voriconazole resistant Candida spp. and Saccharomyces spp. isolates from oropharyngeal candidiasis from Cambodian children with AIDS not pretreated with azoles (letter).
Shahum A; Liskova A; Kalavsky E; Krcmery V
Scand J Infect Dis; 2007; 39(3):286-7. PubMed ID: 17366071
[No Abstract] [Full Text] [Related]
24. The impact of polyene, azole, and DNA analogue antimycotics on the cell surface hydrophobicity of Candida albicans and Candida tropicalis in HIV infection.
Anil S; Ellepola AN; Samaranayake LP
Mycopathologia; 2002; 153(4):179-85. PubMed ID: 12014477
[TBL] [Abstract][Full Text] [Related]
25. Aspirochlorine class compounds from Aspergillus flavus inhibit azole-resistant Candida albicans.
Klausmeyer P; McCloud TG; Tucker KD; Cardellina JH; Shoemaker RH
J Nat Prod; 2005 Aug; 68(8):1300-2. PubMed ID: 16124785
[TBL] [Abstract][Full Text] [Related]
26. Characterization of Candida albicans isolates from the oral cavity of HIV-positive patients.
Woldeamanuel Y; Abate D
Ethiop Med J; 1998 Oct; 36(4):235-43. PubMed ID: 11957299
[TBL] [Abstract][Full Text] [Related]
27. [Activity of the azole drugs in vitro against strains of Candida albicans with different codes isolated from the digestive tract in children].
Kurnatowski M; Kurnatowska A; Wasowska-Królikowska K
Wiad Parazytol; 2004; 50(3):387-92. PubMed ID: 16865942
[TBL] [Abstract][Full Text] [Related]
28. Neutrophil phagocytosis in AIDS patients with azole resistant candidiasis.
Diz Dios P; Iglesias I; Valcarcel JP; Ocampo A; Vazquez E; Castro M
Oral Dis; 1997 May; 3 Suppl 1():S113-5. PubMed ID: 9456669
[TBL] [Abstract][Full Text] [Related]
29. Oropharyngeal Candida colonization and human immunodeficiency virus type 1 infection.
Klein RS; Arnsten JH; Sobel JD
J Infect Dis; 2000 Feb; 181(2):812-3. PubMed ID: 10669393
[No Abstract] [Full Text] [Related]
30. [Antifungal drug susceptibility of Candida causing oropharyngeal candidiasis in HIV infected patients].
Dieng Y; Faye-Niang MA; Ndour-Diop A; Sow PS; Dieng T; Soumare M; Bah IB; Faye O; Diop BM; Gaye O; Ndir O; Diallo S
Dakar Med; 2001; 46(1):4-7. PubMed ID: 15773146
[TBL] [Abstract][Full Text] [Related]
31. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1.
Cameron ML; Schell WA; Bruch S; Bartlett JA; Waskin HA; Perfect JR
Antimicrob Agents Chemother; 1993 Nov; 37(11):2449-53. PubMed ID: 8285632
[TBL] [Abstract][Full Text] [Related]
32. [Antimycotic sensitivity of yeast-like fungi isolated from HIV-infected patients].
Polishchuk OI; Pokas OV; Vialykh ZhE; Vasylenko LH; Koltukova NV
Mikrobiol Z; 2007; 69(3):37-43. PubMed ID: 17682529
[TBL] [Abstract][Full Text] [Related]
33. In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves.
Li Y; Sun S; Guo Q; Ma L; Shi C; Su L; Li H
J Antimicrob Chemother; 2008 Mar; 61(3):577-85. PubMed ID: 18194958
[TBL] [Abstract][Full Text] [Related]
34. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
Rautemaa R; Richardson M; Pfaller MA; Perheentupa J; Saxén H
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):182-5. PubMed ID: 18597968
[TBL] [Abstract][Full Text] [Related]
35. Mutations in the CgPDR1 and CgERG11 genes in azole-resistant Candida glabrata clinical isolates from Slovakia.
Berila N; Borecka S; Dzugasova V; Bojnansky J; Subik J
Int J Antimicrob Agents; 2009 Jun; 33(6):574-8. PubMed ID: 19196495
[TBL] [Abstract][Full Text] [Related]
36. Comparison of three methods for testing azole susceptibilities of Candida albicans strains isolated sequentially from oral cavities of AIDS patients.
Tortorano AM; Viviani MA; Barchiesi F; Arzeni D; Rigoni AL; Cogliati M; Compagnucci P; Scalise G
J Clin Microbiol; 1998 Jun; 36(6):1578-83. PubMed ID: 9620380
[TBL] [Abstract][Full Text] [Related]
37. [Antimycotic therapy impact on oral mucosa Candida species composition in HIV-infected patients].
Filina YS; Shatokhin AI; Volchkova EV; Nesvizhskiy YV; Pak SG
Stomatologiia (Mosk); 2018; 97(6):28-33. PubMed ID: 30589421
[TBL] [Abstract][Full Text] [Related]
38. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy.
Heald AE; Cox GM; Schell WA; Bartlett JA; Perfect JR
AIDS; 1996 Mar; 10(3):263-8. PubMed ID: 8882665
[TBL] [Abstract][Full Text] [Related]
39. In Candida albicans, resistance to flucytosine and terbinafine is linked to MAT locus homozygosity and multilocus sequence typing clade 1.
Odds FC
FEMS Yeast Res; 2009 Oct; 9(7):1091-101. PubMed ID: 19799637
[TBL] [Abstract][Full Text] [Related]
40. Genesis of Azole Antifungal Resistance from Agriculture to Clinical Settings.
Azevedo MM; Faria-Ramos I; Cruz LC; Pina-Vaz C; Rodrigues AG
J Agric Food Chem; 2015 Sep; 63(34):7463-8. PubMed ID: 26289797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
